Sara Feola et al. developed a peptide-based oncolytic vaccine, PeptiCab, which uses oncolytic adenovirus (AdCab) carrying programmed death-ligand 1 (PD-L1) checkpoint inhibitors and combines with MHC-I restricted tumor peptides. Here, CD274 is linked to neoplasm.